PDS Biotechnology Corporation Common Stock

Day range

$1.03 – $1.10

Open

$1.07

Prev close

$1.11

Volume

1.82M

Market cap

$80.45M

Shares out

105.01M

P/E

—

P/S

—

P/B

-22.47

P/FCF

—

ROE

940.6%

ROA

-382.3%

Debt/Equity

-1.22

Div yield

0.00%

As of Oct 23, 2026

• Investor presentationOct 21, 2026

  On October 20, 2026, the Company updated its corporate presentation deck. A copy of the corporate presentation deck is filed herewith as Exhibit 99.1 and incorporated by reference herein.

• Director appointmentOct 20, 2026

  Following the resignations, on October 18, 2026, the Board appointed Deborah A. Ramsdell, John A. Dawson CBE and Bruce Wendel ... as directors of the Company, effective immediately, to fill three of the four vacancies created by the resignations described above.

• Investor presentationSep 21, 2026

  On September 21, 2026, the Company updated its corporate presentation deck. A copy of the corporate presentation deck is filed herewith as Exhibit 99.1 and incorporated by reference herein.

• Private placementSep 14, 2026

  Pursuant to the Purchase Agreement, Nant ... purchased an aggregate of 13,005,334 shares of Common Stock, 22,392,896 pre-funded warrants and 17,699,115 common warrants for a subscription amount of approximately $10.0 million at the initial closing on September 14, 2026.

• Private placementSep 8, 2026

  The Company entered into a Securities Purchase Agreement with certain accredited investors, pursuant to which the Company agreed to issue and sell shares of Common Stock, common stock purchase warrants and/or pre-funded common stock purchase warrants in an unregistered private placement. The aggregate gross proceeds expected at the Initial Closing are approximately $11,550,000.

Days to cover

1.0

Short interest

2.77M

Avg volume

29.13M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors
  positiveGlobeNewswire Inc.· Oct 20, 2026
• PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?
  positiveZacks Investment Research· Oct 14, 2026
• Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care
  positiveGlobeNewswire Inc.· Sep 30, 2026
• Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
  positiveGlobeNewswire Inc.· Jul 21, 2026
• Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
  positiveGlobeNewswire Inc.· Jul 13, 2026